1383920-40-8
1383920-40-8
Chemical Structure
Phytanic acid-d3
- CAS No.: 1383920-40-8
- Formula:C20H37D3O2
- Molecular Weight:315.55
IUPAC Name: 7,11,15-trimethyl-3-(methyl-d3)hexadecanoic acid
InChIKey: RLCKHJSFHOZMDR-VPYROQPTSA-N
SMILES: CC(C)CCCC(C)CCCC(C)CCCC(C([2H])([2H])[2H])CC(O)=O
Biological Activity: Phytanic acid-d3 is the deuterium labeled Phytanic acid[1]. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease[2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Phytanic acid-d3 | 98.95% | Phytanic acid-d3 is the deuterium labeled Phytanic acid. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phytanic acid-d39 | Phytanic acid-d39 is the deuterium labeled Phytanic acid. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phytanic acid | 99.49% | Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Budden SS, et al. Dysmorphic syndrome with phytanic acid oxidase deficiency, abnormal very long chain fatty acids, and pipecolic acidemia: studies in four children. J Pediatr. 1986 Jan;108(1):33-9. [Content Brief]
- [3]. McLean BN, et al. A new defect of peroxisomal function involving pristanic acid: a case report. J Neurol Neurosurg Psychiatry. 2002 Mar72(3):396-9. [Content Brief]
- [4]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov44(5):720-30. [Content Brief]
- [5]. Poll-The BT, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis. 19869(2):169-74. [Content Brief]
- [6]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug39(35):5709-5720. [Content Brief]
